title: [Clozapine: Latest FDA recommendations and our practice].
authors.affiliation: Service de psychiatrie d'adultes, secteur 93G04, EPS Ville-Evrard, 5, rue du Docteur-Delafontaine, 93200 Saint-Denis, France. Electronic address: f.mouaffak@epsve.fr.
authors.forename: F
authors.initials: F
authors.lastname: Mouaffak
authors.affiliation: Pharmacie, EPS de Ville-Evrard, 202, avenue Jean-Jaurès, 93332 Neuilly-sur-Marne cedex, France.
authors.forename: S
authors.initials: S
authors.lastname: Foulon
authors.affiliation: Pharmacie, EPS de Ville-Evrard, 202, avenue Jean-Jaurès, 93332 Neuilly-sur-Marne cedex, France.
authors.forename: F
authors.initials: F
authors.lastname: Smail
authors.affiliation: Pharmacie, EPS de Ville-Evrard, 202, avenue Jean-Jaurès, 93332 Neuilly-sur-Marne cedex, France.
authors.forename: G
authors.initials: G
authors.lastname: Willoquet
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D003024:Clozapine / Q000627:therapeutic use*; D004351:Drug Resistance; D017408:Guidelines as Topic; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D014150:Antipsychotic Agents; D003024:Clozapine